Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
For better result, minimum character length is four(4)
CBT 200 Takes A Modest Loss. More details...
Lipitor Against Zocor Is Mostly A Draw. More details...
CBT 200 Climbs Again. More details...
Restructuring Plan Not Well Received. More details...
Biotech Suffers Biggest Loss in 7 Weeks. More details...
Why Is The FDA Dragging Its Feet?. More details...
What Happened To The Drug?. More details...
CBT 200 Gains 15 Points. More details...
CBT 200 Drops 23 Points. More details...
CBT 200 Slides 8 Points Lower. More details...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China